February 25, 2020 / 7:12 AM / in a month

BRIEF-Lysogene Receives FDA Fast Track Designation For LYS-SAF302

Feb 25 (Reuters) - LYSOGENE SA:

* LYSOGENE RECEIVES FDA FAST TRACK DESIGNATION FOR LYS-SAF302 GENE THERAPY IN MPS IIIA

* LYSOGENE SA SAYS 17TH PATIENT DOSED IN ONGOING PHASE 2/3 AAVANCE STUDY

* TODAY ANNOUNCED THAT U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK DESIGNATION TO ITS LYS-SAF302 PROGRAM FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IIIA (MPS IIIA)

* WE ARE FULLY DEDICATED TO CONTINUE FULL SPEED DEVELOPMENT OF LYS-SAF302, AS WELL AS ALL OTHER PROGRAMS IN OUR PIPELINE - CEO Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below